24/7 Market News Snapshot 19 May, 2025 – Armata Pharmaceuticals, Inc. Common Stock (NYSE:ARMP)

May 19, 2025

DENVER, Colo., 19 May, 2025 (www.247marketnews.com) – (NYSE:ARMP) are discussed in this article.
Armata Pharmaceuticals, Inc. has reported a significant surge in its stock, with pre-market trading reflecting an 11.78% increase, rising to $1.509 from a previous close of $1.350. This uptick, complemented by a trading volume of approximately 645.96K shares, signals robust investor interest and a positive market sentiment, likely influenced by the recent announcements regarding the company’s promising clinical developments.

In particular, Armata has unveiled encouraging topline results from its Phase 1b/2a diSArm trial, which evaluated AP-SA02, a pioneering intravenous bacteriophage therapeutic designed to treat Staphylococcus aureus bacteremia (SAB). The trial has confirmed that AP-SA02 not only meets primary safety and tolerability endpoints but also exhibits a significant improvement in clinical outcomes versus traditional antibiotic therapies.

The multicenter study involved 50 adult participants in the intent-to-treat population, with those receiving AP-SA02 exhibiting an impressive responder rate of 88% at the Test of Cure assessment, compared to 58% for the placebo group. Remarkably, all patients treated with AP-SA02 cleared their MRSA infections without any relapses, reinforcing the therapeutic’s effectiveness even in the presence of antibiotic resistance.

Dr. Deborah Birx, CEO of Armata, emphasized the importance of these findings, stating that the diSArm trial has provided critical insights into the viability of phage therapy for addressing serious infections. The safety profile of AP-SA02 was equally noteworthy, with no serious treatment-related adverse events reported, reinforcing its potential as a novel intervention in the fight against antibiotic-resistant infections.

With successful outcomes from this trial, Armata is positioned to advance to pivotal trials for commercialization, solidifying its commitment to innovation in phage therapy and addressing the rising challenge of antibiotic resistance in healthcare.

Related news for (ARMP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.